Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
Want to see HK:3347 full AI Analyst Report?
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$28.12 - HK$60.60
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$35.11B
Enterprise ValueHK$28.60B
Total Cash (Recent Filing)HK$2.20B
Total Debt (Recent Filing)HK$1.53B
Price to Earnings (P/E)41.7
Beta1.88
Next Earnings
Aug 20, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)0.90
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$54.07Price Target Upside0.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.29
Revenue Forecast (FY)HK$8.75B
Bulls Say, Bears Say
Bulls Say
End-to-end CRO Business Model And International FootprintTigermed’s full-service CRO model covering planning, execution, data, regulatory and safety creates recurring, multi-service engagements. An international delivery network lets it compete for multi-country programs, supporting durable revenue visibility from multi-year clinical pipelines and client stickiness.
Conservative Balance Sheet With Low LeverageLow reported debt (~7% of capital) and a sizeable equity base provide financial flexibility for bidding on large, multi-site trials and for absorbing timing lags in milestone payments. This reduces refinancing risk and supports sustained investment in clinical delivery capacity over months to years.
Positive, Growing Free Cash Flow And Decent Cash ConversionConsistent, growing free cash flow that approximates reported earnings (about 83%) indicates the business converts service revenues into distributable cash. That cash support allows reinvestment in operational capacity and funds working capital needs during long clinical programs, enhancing long-term resilience.
Bears Say
Margin And Return Compression From Peak LevelsReported margins have contracted materially from 2021–2022 peaks, with a 2024 revenue dip before recovery. Persistent margin compression could reflect more competitive pricing, mix shifts to lower-margin work, or higher operating costs, limiting durable profitability unless structural drivers reverse.
Modest Returns On Equity (low ROE)A TTM ROE near ~4% signals limited efficiency in converting equity into profit versus historical highs. Low capital returns constrain the company’s ability to generate shareholder value from existing assets absent operational improvements or higher-margin contract wins over the medium term.
Weaker Operating Cash Conversion RecentlyWhile FCF is positive, operating cash flow has covered a smaller portion of earnings recently, pointing to less consistent cash conversion. For a service business with long billing cycles, inconsistent OCF increases working capital strain risk and could pressure investments or margins over time.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$28.12 and its highest was HK$60.60 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$35.11B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 64 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.069 earnings per share for the quarter, missing the consensus estimate of HK$0.274 by -HK$0.205.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.145 which represents an annual dividend yield of 0.8%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.38.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of HK$0.069 in its last earnings report, missing expectations of HK$0.274. Following the earnings report the stock price went up 3.774%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.69%
Trailing 12-Months
Asset Growth
-1.34%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization (CRO) across the People's Republic of China and globally, offering an extensive suite of services. The company's operations are divided into two primary segments: Clinical Trial Solutions and Clinical-related and Laboratory Services. Its service portfolio includes support for regulatory submissions and approvals, medical translation, and Good Manufacturing Practice (GMP) consulting. Tigermed provides comprehensive clinical services, addressing areas such as medical science, early-phase and late-phase clinical development, medical monitoring, project management, patient enrollment, and quality management systems. Biometrics services encompass data management, biostatistics, and statistical programming. Moreover, the company delivers integrated technology solutions, featuring site management, pharmacovigilance, independent audit and training programs, medical imaging, clinical trial system development, central laboratory functions, pre-clinical investigations, and research hospital support. For medical devices and in vitro diagnostics (IVD), Tigermed offers specialized services like product testing, regulatory submissions, clinical evaluations and trials, GMP certification, EU MDR and IVDR readiness, and supplementary value-added services. Its expertise also extends to post-marketing studies, real-world evidence generation, and clinical trials for vaccines. Hangzhou Tigermed Consulting Co., Ltd. was established in 2004 and is headquartered in Hangzhou, PRC.
3347 Stock 12 Month Forecast
Average Price Target
HK$54.07
▲(0.13% Upside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―
Options Prices
Currently, No data available
---